PMID- 18643855
OWN - NLM
STAT- MEDLINE
DCOM- 20090514
LR  - 20151119
IS  - 1468-1293 (Electronic)
IS  - 1464-2662 (Linking)
VI  - 9
IP  - 8
DP  - 2008 Oct
TI  - Effect of haematological alterations on thalassaemia investigation in 
      HIV-1-infected Thai patients receiving antiretroviral therapy.
PG  - 660-6
LID - 10.1111/j.1468-1293.2008.00617.x [doi]
AB  - OBJECTIVES: To evaluate the effect of haematological alterations resulting from 
      antiretroviral therapy (ART) on the diagnosis of thalassaemia carriers in 
      HIV-1-infected Thai patients. METHODS: Complete blood cell counts, osmotic 
      fragility (OF) test and haemoglobin (Hb)-A(2) values were measured in blood 
      samples of 52 antiretroviral-treated and 14 untreated HIV-1-infected patients. 
      Data were analysed according to thalassaemia type and ART. RESULTS: Sixteen 
      patients carried at least one of the investigated thalassaemia types and most of 
      them (87.5%) received ART. Their red cell indices [mean corpuscular Hb (MCH), 
      mean corpuscular Hb concentration (MCHC) and red blood cell distribution width 
      (RDW)], OF test and Hb-A(2) values were observed within the critical criteria of 
      each thalassaemia type. Normocytic red cells were observed in alpha-thalassaemia 
      and Hb-E trait. Among HIV-1-infected patients who are non-thalassaemia carriers, 
      higher values of Hb-A(2), MCH, macrocytosis and lower red cell counts were 
      observed in the treated group. Values of RDW, MCHC and OF test for treated and 
      untreated groups were in the normal range. Five treated patients had Hb-A(2) 
      values within the critical criteria of beta-thalassaemia carriers but 
      beta-thalassaemia gene mutations were not observed by polymerase chain reaction 
      analysis. CONCLUSIONS: ART can alter many haematological figures. Therefore, 
      diagnosis of thalassaemia should be evaluated carefully in combination with those 
      parameters.
FAU - Pornprasert, S
AU  - Pornprasert S
AD  - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang 
      Mai University, Chiang Mai, Thailand. sakornmi001@yahoo.com
FAU - Leechanachai, P
AU  - Leechanachai P
FAU - Klinbuayaem, V
AU  - Klinbuayaem V
FAU - Leenasirimakul, P
AU  - Leenasirimakul P
FAU - Sukunthamala, K
AU  - Sukunthamala K
FAU - Thunjai, B
AU  - Thunjai B
FAU - Phusua, A
AU  - Phusua A
FAU - Saetung, R
AU  - Saetung R
FAU - Sanguansermsri, T
AU  - Sanguansermsri T
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20080717
PL  - England
TA  - HIV Med
JT  - HIV medicine
JID - 100897392
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Biomarkers)
RN  - 0 (stavudine, lamivudine, nevirapine drug combination)
RN  - 2T8Q726O95 (Lamivudine)
RN  - 9034-52-0 (hemoglobin A2')
RN  - 9034-53-1 (Hemoglobin A2)
RN  - 99DK7FVK1H (Nevirapine)
RN  - BO9LE4QFZF (Stavudine)
SB  - IM
MH  - Adult
MH  - Anti-Retroviral Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Case-Control Studies
MH  - Erythrocyte Indices
MH  - Female
MH  - HIV Infections/*blood/*drug therapy
MH  - *HIV-1
MH  - Hemoglobin A2/analysis
MH  - Humans
MH  - Lamivudine/*therapeutic use
MH  - Male
MH  - Nevirapine/*therapeutic use
MH  - Osmotic Fragility
MH  - Stavudine/*therapeutic use
MH  - Thalassemia/*blood/*diagnosis
MH  - Young Adult
EDAT- 2008/07/23 09:00
MHDA- 2009/05/15 09:00
CRDT- 2008/07/23 09:00
PHST- 2008/07/23 09:00 [pubmed]
PHST- 2009/05/15 09:00 [medline]
PHST- 2008/07/23 09:00 [entrez]
AID - HIV617 [pii]
AID - 10.1111/j.1468-1293.2008.00617.x [doi]
PST - ppublish
SO  - HIV Med. 2008 Oct;9(8):660-6. doi: 10.1111/j.1468-1293.2008.00617.x. Epub 2008 
      Jul 17.